newsfilter
← Latest News
GlobeNewswire·

Trillium Announces Pricing of US$130 Million Public Offering of Common Shares

CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...